Evidence map›Paper›PMID 40645180›Full record

ArticleMolecular cell2025

FMRP drives mRNP targets into translationally silenced complexes.

Tatsuaki Kurosaki, Hana Cho, Elizabeth T Abshire, Christoph Pröschel, Shuhei Mitsutomi, Hanae Sato, Eric A J Simko, Christopher S Fraser, Hitomi Sakano, Lynne E Maquat

Abstract read
In one paragraph

Article in Molecular cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tatsuaki KurosakiDepartment of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA; Center for RNA Biology, University of Rochester, Rochester, NY 14642, USA; Department of Biotechnical and Clinical Laboratory Sciences, Jacobs School of Medicine & Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY 14214, USA.
Hana ChoDepartment of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA; Center for RNA Biology, University of Rochester, Rochester, NY 14642, USA.
Elizabeth T AbshireDepartment of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA; Center for RNA Biology, University of Rochester, Rochester, NY 14642, USA.
Christoph PröschelCenter for RNA Biology, University of Rochester, Rochester, NY 14642, USA; Department of Biomedical Genetics, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA; Stem Cell and Regenerative Medicine Institute, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA.
Shuhei MitsutomiDepartment of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA; Center for RNA Biology, University of Rochester, Rochester, NY 14642, USA.
Hanae SatoDepartment of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA; Center for RNA Biology, University of Rochester, Rochester, NY 14642, USA.
Eric A J SimkoNational Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.
Christopher S FraserDepartment of Molecular and Cellular Biology, College of Biological Sciences, University of California, Davis, Davis, CA 95616, USA.
Hitomi SakanoCenter for RNA Biology, University of Rochester, Rochester, NY 14642, USA; Department of Otolaryngology, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA.
Lynne E MaquatDepartment of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA; Center for RNA Biology, University of Rochester, Rochester, NY 14642, USA. Electronic address: lynne_maquat@urmc.rochester.edu.

Funding

University of Rochester Intellectual and Developmental Disabilities Research CenterP50HD103536 · NICHD · UNIVERSITY OF ROCHESTER · PI Leona Ashley Oakes · 2020 to 2026
$9.8M
REGULATION OF SELENOPROTEIN RNA METABOLISMR01GM059614 · NIGMS · UNIVERSITY OF ROCHESTER · PI MAQUAT, LYNNE E · 1999 to 2022
$9.1M
Nonsense-mediated mRNA decay and beyondR35GM149268 · NIGMS · UNIVERSITY OF ROCHESTER · PI Lynne E Maquat · 2023 to 2026
$3.1M
The mechanisms of mRNA recruitment to the human ribosomeR35GM152137 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Christopher S Fraser · 2024 to 2026
$1.3M
Orbitrap Fusion Lumos Mass Spectrometer for UR Proteomics ResearchS10OD025242 · OD · UNIVERSITY OF ROCHESTER · PI GHAEMMAGHAMI, SINA · 2018 to 2018
$1.1M
Role of Fragile X Mental Retardation Protein on Gene Expression in Auditory Brainstem DevelopmentK08DC019416 · NIDCD · UT SOUTHWESTERN MEDICAL CENTER · PI SAKANO, HITOMI · 2021 to 2025
$915k
Suppression of Dominant-Negative Transcripts Escaping from Nonsense-Mediated mRNA DecayR21GM147719 · NIGMS · UNIVERSITY OF ROCHESTER · PI KUROSAKI, TATSUAKI · 2022 to 2023
$383k
Regulation of exon junction complex composition and assemblyK99GM152790 · NIGMS · UNIVERSITY OF ROCHESTER · PI ABSHIRE, ELIZABETH TENLEY · 2024 to 2025
$250k
NICHD NIH HHS P50 HD103536NIDCD NIH HHS K08 DC019416NIGMS NIH HHS K99 GM152790NIGMS NIH HHS R01 GM059614NIGMS NIH HHS R21 GM147719NIGMS NIH HHS R35 GM149268NIGMS NIH HHS R35 GM152137NIH HHS S10 OD025242
6 · The paper itself

Abstract

Fragile X syndrome (FXS) results from a deficiency of the ubiquitously expressed RNA-binding protein fragile X protein (FMRP). While FMRP-mediated translational repression has been attributed primarily to ribosome stalling, using immunoprecipitations and polysome profiling of non-polar- and polar-cell lysates and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses, we show that mammalian FMRP largely represses translation initiation by associating with granule constituents to preclude 40S ribosomal subunit binding. We demonstrate that FMRP associates with its target mRNAs by binding directly to eukaryotic translation initiation factor 4E (eIF4E) at the 5' cap in competition with eIF4G1 and that ataxin-2-like promotes FMRP binding to the transcribed body. The KH1 + KH2 domains of FMRP are critical for the co-immunoprecipitation of eIF4E, mRNA targets, ataxin-2-like, and PABPC1. Our findings supplement FMRP-mediated ribosome-stalling data, suggesting that FMRP largely mediates the sequestration of its mRNA targets from translation initiation and degradation in a network of FMRP molecules that simultaneously associate with cap-bound eIF4E, GC-rich mRNA regions, and poly(A)-bound PABPC1.

Indexed as

Fragile X Messenger Ribonucleoprotein 1Fragile X SyndromeProtein BiosynthesisRibonucleoproteinsAnimalsEukaryotic Initiation Factor-4EEukaryotic Initiation Factor-4GHEK293 CellsHumansMiceNerve Tissue ProteinsPeptide Chain Initiation, TranslationalPoly(A)-Binding Protein IPolyribosomesProtein BindingRibosomeseIF4E protein, mouseEukaryotic Initiation Factor-4EEukaryotic Initiation Factor-4GFMR1 protein, humanFmr1 protein, mouseFragile X Messenger Ribonucleoprotein 1messenger ribonucleoproteinNerve Tissue ProteinsPoly(A)-Binding Protein IRibonucleoproteinsRNA, Messengerataxin-2-likeeIF4Eembryonic human cortical neuronsFMRPFragile X syndromeLC-MS/MSmRNPPABPC1post-natal mouse cortextranslational repression

Identifiers

PMID40645180
PMCPMC12258928

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.